Pfizer announced that it stopped its research to find new drugs to treat Alzheimer’s and Parkinson’s disease. According to the company, it wants to realign their focus on areas where they are strongest.
Pfizer was one of the pharmaceutical companies, along with Eli Lilly and GlaxoSmithKline, which established the Dementia Discovery Fund in 2015. Its goal is to develop drugs and other treatments for Alzheimer’s disease. During that time, the company was proud to lead its expertise in advancing the studies for therapies and cures for patients suffering from dementia.
Disappointment for Pfizer
Throughout the years, there was nothing but disappointment for Pfizer regarding its Alzheimer’s disease research. The company was optimistic about the drug bapineuzumab, but it failed to show positive results during its second round of trials. That’s why the company and its partner Johnson and Johnson stopped additional research on the drug in 2012. The most recent failure was the drug call PF-05212377, which also failed to meet its goals.
It is not just a big blow to Alzheimer’s and Parkinson’s disease patients. In the next couple of months, Pfizer will have several rounds of layoffs at its research and development facilities in the United States.
The Future of Alzheimer’s Disease Treatments
As one of the major pharmaceutical companies, Pfizer’s abandonment of Alzheimer’s and Parkinson’s disease research is alarming. It might make other drug makers to stop their research into the central nervous system and the brain as well.
Pfizer’s failures can also lead to new methods of treating the disease. Pfizer and other drug manufacturers focused on developing drugs that eliminate amyloid plaques. However, all their drugs failed to target the biological markers of the disease. Researchers must find new approaches to developing drugs that can stop, prevent, or slow down the effects of the disease.